251 related articles for article (PubMed ID: 29368127)
1. Efficacy and Safety of Tiotropium in Children and Adolescents.
Hamelmann E; Szefler SJ
Drugs; 2018 Mar; 78(3):327-338. PubMed ID: 29368127
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium for the treatment of asthma in adolescents.
Hamelmann E; Vogelberg C; Szefler SJ
Expert Opin Pharmacother; 2017 Feb; 18(3):305-312. PubMed ID: 28110558
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
[TBL] [Abstract][Full Text] [Related]
4. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
[TBL] [Abstract][Full Text] [Related]
5. Safety of tiotropium Respimat
Graham LM; Kerstjens HAM; Vogelberg C; Hamelmann E; Szefler SJ; Pisternick-Ruf W; Engel M; El Azzi G; Unseld A; Foggs MB
Respir Med; 2019 Aug; 155():58-60. PubMed ID: 31302579
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium for the treatment of asthma: a drug safety evaluation.
Kerstjens HA; O'Byrne PM
Expert Opin Drug Saf; 2016 Aug; 15(8):1115-24. PubMed ID: 27279414
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.
Szefler SJ; Murphy K; Harper T; Boner A; Laki I; Engel M; El Azzi G; Moroni-Zentgraf P; Finnigan H; Hamelmann E
J Allergy Clin Immunol; 2017 Nov; 140(5):1277-1287. PubMed ID: 28189771
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.
Vogelberg C; Engel M; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Downie J; Nething K; Vevere V; Vandewalker M
Respir Med; 2014 Sep; 108(9):1268-76. PubMed ID: 25081651
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
10. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.
Halpin DM; Kaplan AG; Russell RK
Respir Med; 2017 Jul; 128():28-41. PubMed ID: 28610667
[TBL] [Abstract][Full Text] [Related]
11. Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.
Vogelberg C; Szefler SJ; Vrijlandt EJLE; Boner AL; Engel M; El Azzi G; Vulcu SD; Moroni-Zentgraf PM; Eickmeier O; Hamelmann EH
Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 31097514
[TBL] [Abstract][Full Text] [Related]
12. A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma.
Meltzer EO; Berger WE
Allergy Asthma Proc; 2018 Jan; 39(1):14-26. PubMed ID: 29279056
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis.
Konstan MW; Sharma A; Moroni-Zentgraf P; Wang F; Koker P
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):137-44. PubMed ID: 25380193
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis.
Wang L; Zhou R; Xie X
J Asthma; 2019 Jan; 56(1):69-78. PubMed ID: 29420077
[TBL] [Abstract][Full Text] [Related]
15. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists.
McKeage K
Drugs; 2015 May; 75(7):809-16. PubMed ID: 25895466
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.
Buhl R; FitzGerald JM; Meltzer EO; de la Hoz A; Sigmund R; Kerstjens HAM; Bleecker ER
Pulm Pharmacol Ther; 2020 Feb; 60():101881. PubMed ID: 31874283
[TBL] [Abstract][Full Text] [Related]
18. Burden of Asthma and Role of 2.5 µg Tiotropium Respimat
Mansfield L; Duong-Quy S; Craig T
Adv Ther; 2019 Oct; 36(10):2587-2599. PubMed ID: 31435830
[TBL] [Abstract][Full Text] [Related]
19. Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Busse WW; Dahl R; Jenkins C; Cruz AA
Eur Respir Rev; 2016 Mar; 25(139):54-64. PubMed ID: 26929422
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics.
Casale TB; Aalbers R; Bleecker ER; Meltzer EO; Zaremba-Pechmann L; de la Hoz A; Kerstjens HAM
Respir Med; 2019; 158():97-109. PubMed ID: 31654891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
